Track record · closed signal

BioMarin Pharmaceutical Inc. (BMRN) — closed signal from December 19, 2025

Partial Published before the outcome was known, scored automatically when the window closed on March 19, 2026.

Predicted vs. what happened

BMRN price · publication thesis → realized outcomesplit-adjusted
$59.73 Published $80.64 Target $55.43 Window close $66.28 Peak
$57.50 – $61.00Entry zone — fair-value band
$59.73Published — price the day we called it
$80.64Target — the price the thesis aimed for
$66.28Peak — highest point inside the window, not a realized return
$55.43Window close — end-of-window price, context only

What happened

Partial

Reached 31% of the predicted growth at its peak, without hitting the target.

Peak price
$66.28
peak on February 24, 2026 — not a realized return
Peak gain
+11%
peak, from the publication price
Window close
$55.43
end-of-window price, context only
Days to target
—
Window
December 19, 2025 – March 19, 2026

The thesis — published December 19, 2025

Predicted growth
+35%
over the measurement window
Target price
$80.64
the price the thesis aimed for
Entry zone
$57.50 – $61.00
the fair-value band we waited for
Price at publication
$59.73
published December 19, 2025
Confidence
75%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

This is a short-term trade idea where the stock could move back toward normal levels. The company announced a $500M cost program, about two-thirds done, aiming for a 40% operating margin next year. Options show high uncertainty, which often comes before a big move. Because the setup depends on market positioning, use confirmation and strict stops.

Primary drivers

  • Cost program could change how investors value the company
  • Options pricing shows market expects a big near-term move
  • Very oversold price makes a rebound more likely
  • Slow fundamentals versus market mood raise chance of a failed bounce

How it played out

BMRN: target was not reached

Lyra published BMRN at 59.73 on 2025-12-19 as a short-term rebound idea with 35% expected growth. The thesis pointed to a $500M cost program that was about two-thirds done, a 40% operating margin aim for next year, options pricing that showed high uncertainty, and an oversold setup. It also noted that slow fundamentals and market mood raised the risk of a failed bounce.

Inside the window, BMRN rose to 66.28 on 2026-02-24. That was an 11% peak gain, but it stayed below the 80.64 target. It ended the window at 55.43. The thesis partially played out, then missed the target.

What happened during the window

On 2025-12-19, BioMarin agreed to buy Amicus Therapeutics for about $4.8 billion in cash. The deal was expected to close in the second quarter of 2026.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BMRN signals